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Thrombocytopenia or platelet deficiency is a condition, in which platelet level in the 
blood circulation is below normal, which is less than 150,000 cells/µl. 
Thrombocytopenia is classified into some conditions, including decreased platelet 
production, increased need for platelets, and other thrombocytopenia. The need for 
increased platelets can be subdivided into primary immune thrombocytopenia, 
secondary immune thrombocytopenia, non-primary ITP, and thrombocytopenia that 
are not immune-mediated. Several cytokines play a role in the process of  
thrombocytopenia, one of  which is Interleukin-17 (IL-17) that will be further 
discussed in this study. A previous study reported that IL-17 production increased in 
ITP and cITP patients. The objective of  this study was to analyze the IL-17 levels and 
figure out the differences in IL-17 levels in the serums of  patients with primary ITP 
and secondary ITP. The samples were taken from Wahidin Sudirohusodo Hospital and 
the specimens were examined in the Research Unit Laboratory of  the Faculty of  
Medicine, Universitas Hasanuddin/Hospital of  Universitas Hasanuddin. The 
comparative test resulted in p-value = 0.005, where p <α = 0.05; and therefore, there 
was a significant difference between IL 17 levels in ITP and non-primary ITP. 
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INTRODUCTION  
Platelets are also called blood chips, 
megakaryocyte cytoplasmic fragments that do not 
have a nucleus and are formed by bone marrow 
(Kosasih, 2008). The normal platelet level ranges 
between 150,000 - 400,000 cells/μl of  blood 
(Lefever Joyce, 2008). Thrombocytopenia or 
platelet deficiency is a condition where the 
platelets in the circulatory system are below 
normal (Guyton and Hall, 2014). 
Thrombocytopenia is classified into 
decreased platelet production, increased platelet 
consumption, and other thrombocytopenia. 
Decreased platelet production is caused by damage 
to the bone marrow, myelofibrosis, 
myelodysplastic syndrome, and iron deficiency. 
Meanwhile, the increased platelets can be further 
divided into primary immune thrombocytopenia, 
secondary immune thrombocytopenia, non-ITP, 
and thrombocytopenia not mediated by immunity 
(Matzdorff  et al., 2018). Primary immune 
thrombocytopenia or Immune 
Thrombocytopenic Purpura (ITP) is an 
autoimmune disorder in the body without other 
secondary causes resulting in a platelet count 
<100,000 cells / µl (Makis et al., 2017), while 
secondary immune thrombocytopenia is a 
condition of  thrombocytopenia attributed to a 
primary disease, which among others are 
autoimmune diseases, particularly the syndromes 
of  anti-phospholipid antibody, Systemic Lupus 
Erythematosus/SLE, Rheumatoid Arthritis/RA, 
Helicobacter pylori infection, viral infections 
(including Hepatitis C and Human 
Immunodeficiency Virus [HIV]), and certain 
drugs (Zufferey, Lime, & Semple, 2017). 
The incidence of  secondary immune 
thrombocytopenia in adults accounts for 18% of  
the incidence of  ITP patients that require health 
care. A total of  5.9% patients have malignant 
lymphoid disorders, 2.5% systemic lupus 
erythematosus, 2.3% myelodysplastic syndrome, 
1.7% immune deficiency (excluding HIV 
infection), 0.9% HIV infection, 0.6% sarcoidosis, 
0.3%, antiphospholipid syndrome, and 0.2% HCV 
infection. Forty-seven adult patients (1.63%) and 
nine children patients (1.1%) suffer from Evans 
syndrome. Secondary immune thrombocytopenia 
occurs in patients at a more mature age than ITP 
patients and is more common to happen in 
women. Only 2.4% of  cases of  secondary immune 
thrombocytopenia occur in children. The main 
causes are primary immune deficiency, systemic 
lupus erythematosus, blood cancer, and HIV 
infection (Moulis et al., 2014). 
ITP disease is a health problem caused by 
immune dysregulation that triggers the loss of  
tolerance of  the immune system to self-antigens 
on the surface of  platelets and megakaryocytes. T 
cells are activated due to the introduction of  
platelet-specific antigens to APC (antigen-
presenting cells), which then induce antigen-
specific expansion in B cells. B cells then produce 
glycoprotein-specific autoantibodies that are 
expressed on platelets and megakaryocytes. The 
circulating platelets are bound by platelet 
autoantibodies and then adhere to the spleen 
macrophage FC receptor, which results in platelet 
destruction. In addition, anti-megakaryocyte 
autoantibodies are also formed and these reduce 
the ability of  megakaryocytes to produce platelets 
(Sari, 2018). The research conducted by Li et al. 
(2015) reported that the levels of  IL-17A in cITP 
(chronic Immune Thrombocytopenic Purpura) 
patients were significantly higher than in the 
controls. Further, the study by Ye (2015) found 
that ITP patients showed increased levels of  
mRNA expression in IL-23p19, IL-12p40, IL-
23R, IL-12Rβ1, IL-17A, IL-17F, and RORC. 
Moreover, there were increases in Th17 cells and 
IL-17 levels in plasma. 
The results of  previous studies highlighted 
an increase in the number of  patients with 
autoimmune thrombocytopenia. As science 
develops, it turns out that IL-17 cytokines play a 
particular role in ITP; however, further analysis of  
IL-17 in secondary immune thrombocytopenia 
has not been carried out. Therefore, the 
researchers were triggered to analyze IL-17 levels 
in the serums of  ITP and non-primary ITP 
patients, and compare the results of  IL-17 levels in 
both types of  serums. 
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MATERIALS AND METHODS 
This research belongs to an analytical study 
with a cross-sectional approach. This study was 
carried out in August – December 2019. The data 
used in this study were primary. The samples were 
taken from Wahidin Sudirohusodo Hospital and 
specimens were examined in the Research Unit 
Laboratory of the Faculty of Medicine, Universitas 
Hasanuddin/Hospital of Universitas Hasanuddin. 
The samples were all patients diagnosed with 
autoimmune thrombocytopenia at dr. Wahidin 
Sudirohusodo Hospital and the networks during 
the research period. A total of 60 samples were 
used, which were taken using a purposive sampling 
technique by considering the inclusion and 
exclusion criteria. The criteria of inclusion were: 
(1) the residual samples or patient serums resulted 
from routine blood tests showed a platelet count 
<100,000 μl, (2) the data of medical records of 
patients with ITP without any other blood cell 
abnormalities indicated that the hemoglobin and 
leukocyte levels were normal, and (3) the medical 
record data showed a platelet count <100,000 
cells/μl accompanied by a diagnosis of other 
diseases causing thrombocytopenia, but it was not 
primary ITP. The exclusion criteria were: (1) the 
specimen volume was insufficient and (2) the 
specimens were hemolyzed, lipemic, and icteric 
and the sampling could not be repeated. 
The IL-17 level examination was carried out 
using the ELISA method. 40 μl of samples were 
put into the sample holes and 10 μl of anti-IL-17 
antibody was added. After that, 50 μl of 
streptavidin HRP was added into each sample hole 
and standard hole until homogenized. The plate 
was covered with a lid and incubated at 37 ℃ for 
60 minutes. The lid was removed and the plate was 
washed five times with Wash Buffer. 50 µl of 
substrate solution A was added into each well and 
then 50 µl of substrate solution B was put into 
each well. The plate was later covered with a lid 
and incubated at 37 ℃ for 10 minutes.  
50 μl of Stop solution was added into each 
well and homogenized. The color would turn 
yellow immediately. The absorbance was read at 
450 nm in the microplate reader. Furthermore, the 
data obtained were processed using statistical 
software. 
 
 
RESULT AND DISCUSSION 
The samples in this study were the serums of 
primary ITP and non-primary ITP patients, which 
were then tested for the interleukin-17 levels. A 
total of 60 samples, consisting of ITP samples (24 
women and 6 men) and 30 non-primary ITP 
samples (12 women and 18 men), were used. The 
samples had a platelet count <100,000 cells/μl. 
The samples were taken from patients at Wahidin 
Sudirohusodo Hospital from August to October 
2019. The general characteristics of the research 
subjects are presented in Table 1. 
 
Results of  Comparative Test of  IL-17 Levels 
in the ITP and Non-Primary ITP Subjects 
The test on the differences in IL-17 levels was 
performed using a statistical test, initiated by the 
data normality test. The data normality test with 
the Shapiro-Wilk test resulted in α = 0.05. The 
results of the normality test showed the value of p 
= 0.000, where the p-value was smaller than the 
value of α (p <α), denoting that the data were not 
normally distributed, so the Mann Whitney test 
was used. The Mann Whitney test was conducted 
to spot the differences in the median of the two 
groups. The results of the Mann Whitney test are 
demonstrated in Table 2. 
Based on the results of  the statistical test 
presented in Table 2, the median value of  
interleukin-17 levels in primary ITP was 13.50 and 
the median value of  interleukin-17 levels in non-
primary ITP was 19.50. The results of  the 
statistical test using Mann Whitney also yielded the 
value of  p = 0.005 and the value of  α = 0.05, which 
indicate that the p-value was smaller than the value 
of  α (p <α), exemplifying a significant difference 
between the levels of  interleukin-17 in primary 
ITP and non-primary ITP.
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Table 1. General characteristics of  research subjects 
Parameter Primary ITP (n=30) Non-Primary ITP (n=30) 
n % n % 
Sex Man 
Woman 
6 
24 
20 
80 
18 
12 
60 
40 
Age classification (year) 0 – 17  
18 – 65 
66 – 79  
4 
22 
4 
13.3 
73.3 
13.3 
4 
21 
5 
13.3 
70 
16.6 
Classification of  causes 
of  thrombocytopenia 
a.  PLT destruction 
1. Primary ITP 
2. Secondary ITP 
b. PLT production 
c. Other 
thrombocytopenia 
30 
 
- 
 
- 
- 
100 
 
- 
 
- 
- 
- 
 
7 
 
9 
14 
- 
 
23.3 
 
30 
46.6 
 
 
Table 2. Comparison of  IL-17 levels in primary ITP and non-primary ITP Subjects 
Subyek 
Primary ITP (n=30) Non-Primary ITP (n=30)  *p 
Mean Median SD Mean Median SD  
Interleukin-17 (ng/L) 
17.57 13.50 11.65 126.27 19.50 183.82 0.005 
*p Mann Whitney test 
 
 
The characteristics of  the subjects based on 
gender showed that ITP occurred more in female 
subjects (80%) than in male subjects (20%). This 
ratio is in line with the finding in a previous study 
by Ayesh, Alawneh, Khassawneh, Khader, & 
Kasasbeh (2013), with women and men ratio of  
2.5:1. The latest research conducted by Yun Liang 
from the University of  Michigan reported that 
women were more likely to develop autoimmune 
diseases due to the differences in gene expression 
as many as 661 of  all participants. The study by 
Liang & Gibson (2017) found that women had 
higher risk factors in autoimmune diseases. 
The characteristics of  subjects in this study 
were also classified based on age. Both types of  
thrombocytopenia occurred mostly in patients 
aged 18-75 years old, 73.3% of  ITP subjects, and 
70% of  secondary immune thrombocytopenia 
subjects. The data are following the finding in a 
previous study by Sultan, Ahmed, Murad, & Irfan 
(2016) that ITP patients were predominantly 
found in the 30-year-old age group and occurred 
at the peak age of  ≥ 60 years in developed 
countries. 
Thrombocytopenia is categorized into 
decreased platelet production, increased platelet 
consumption, and other thrombocytopenia. 
Decreased platelet production is attributed to the 
impairment of  the bone marrow, myelofibrosis, 
myelodysplastic syndrome, and iron deficiency. 
Table 1 demonstrates that 43.3% of  non-primary 
ITP subjects had decreased platelet production. In 
this case, some patients suffered from aplastic 
anemia and myelofibrosis, both of  which are 
diseases related to damage to the bone marrow in 
producing blood cells. In aplastic anemia, a 
decrease in the production of  blood cells from the 
bone marrow occurs, triggering reticulocytopenia, 
anemia, granulocytopenia, monocytopenia, and 
thrombocytopenia. Meanwhile, myelofibrosis is 
cancer that occurs in the bone marrow, which 
instigates abnormal development and function of  
red blood cells that can lead to anemia, 
thrombocytopenia, and an enlarged liver.  
The consumption of platelets would increase 
in this study, where ITP occurred in the total 
sufferers. As mentioned earlier, primary immune 
thrombocytopenia is an abnormality in the platelet 
count, in which the platelet count is under the 
normal value, <100,000 cells/μl, without any 
other secondary causes. This disease may be 
resulted from increased platelet destruction by 
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humoral or cellular immune mechanisms, as well 
as improper platelet production in the bone 
marrow. (Aboud, Depré, & Salama, 2017).  
The increase in platelet consumption also 
occurred in secondary ITP, as much as 40% of  the 
total of  30 samples. Secondary ITP was 
accompanied by diseases, such as HIV, HBV, and 
hepatic cirrhosis. The process of  secondary 
immune thrombocytopenia can be explained like 
any other autoimmune process. The body's 
antigens, the HPA, react with the immune system 
in the body. Self-antigens can cross-react with 
microbial antigens and the activity is called 
molecular mimicry. Furthermore, microbes will 
activate specific T cells against self-antigens and 
then an immune response will occur (Abbas, 
Lichtman, & Pillai; 2015). 
Thrombocytopenia not immune-mediated in 
this study were found in patients who experienced 
bleeding and sepsis. Bleeding is a condition where 
the blood comes out of  damaged blood vessels, 
both inside and outside the body. When bleeding 
occurs, the body will try to stop the blood loss, but 
when it is enormously heavy, the production of  
platelets in the body is not enough to overcome 
the bleeding and the body will experience a 
decrease in the number of  platelets. This is similar 
to sepsis; when the tissue is injured or infected, 
there will be a simultaneous release of  pro-
inflammatory and anti-inflammatory factors. The 
balance of  these disparate signals will aid in tissue 
repair and healing. When the inflammatory 
process is not in balance, serious tissue damage 
will happen, and this mediator will produce 
adverse systemic effects on the body. 
This study found patients suspected with 
community-acquired pneumonia, in which 
cytokines increased to control the spread of  
bacterial infections. The study conducted by Jin & 
Dong (2013) confirmed that cytokines IL-17A and 
IL-17F are important in cleaning bacteria, such as 
S. aureus, C. rodentium, and Klebsiella pneumoniae. 
These cytokines increase in bacterial control and 
produce proinflammatory chemokines. 
Sepsis and renal failure were also diagnosed 
in the samples, where sepsis-related renal failure 
would increase IL-17 levels and neutrophils, which 
subsequently triggered apoptosis. The results of  
this study are along the lines with the findings in 
Das & Khader’s research (2017) on in vitro with 
PBMC from healthy donors and patients with 
severe sepsis that reported an increase in Th-17 
cells in patients with sepsis compared to healthy 
donors. 
The results of  the comparative test using 
statistical tests on primary ITP and non-primary 
ITP showed a significant difference in the results 
of  IL-17 levels between primary ITP and non-
primary ITP. This difference occurs because 
patients with non-primary ITP also suffered from 
other diseases, such as sepsis, aplastic anemia, and 
myelofibrosis that could increase the IL-17 levels. 
Interleukin-17 is a strong proinflammatory 
cytokine capable of  recruiting neutrophils and 
monocytes and inducing the activation of  various 
cytokines. Interleukin-17 will increase when it is 
first detected and has never been treated, and IL-
17 levels will increase when the body experiences 
sepsis. 
 
 
CONCLUSION 
This study concludes a significant difference 
between IL-17 levels in primary ITP and non-
primary ITP. 
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